Helix Nanotechnologies
-100%
est. 2Y upside i
Next-generation mRNA platform to solve cancer, COVID and climate.
Rank
#3800
Sector
Biotechnology
Est. Liquidity
~6Y
Data Quality
Data: LowEquity upside appears negligible due to a severe preference stack ($52.5M) far exceeding the current valuation ($3M).
Last updated: July 19, 2026
Even in an optimistic scenario with exit multiple of 7x and revenue growth to $1.2M, exit value of $8.5M is far below $52.5M preference stack, resulting in zero common recovery.
Base case exit multiple of 5x yields $6M exit, still below $52.5M preference, common stock worthless.
Bear case exit multiple of 2x yields $2.4M, well below preference, 100% loss for common shareholders.
Preference Stack Risk
severeFunding Intensity
175000%Total preferred stock liquidation preference of $52.5M dwarfs the $3M company valuation; common stock is deeply out of the money.
Dilution Risk
highWith only 17 employees and $1M revenue, a capital raise within 12-18 months is likely, further diluting common.
Secondary Liquidity
noneNo secondary market activity, no recent secondary trades.
Questions to Ask at the Interview
Strategic questions based on Helix Nanotechnologies's data — designed to show you've done your homework.
- 1
“What is the current common stock 409A valuation and how does it relate to the $52.5M aggregate preferred liquidation preference?”
- 2
“What are the key value inflection points (e.g., trial results, partnership) that could significantly raise the company's valuation?”
- 3
“Given the current cap table, what is the typical dilution for new hires at this stage?”
Community
Valuation Sentiment
Our model estimates -100% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.